THERAPY DOSSIER · th-42b2a1de418c

Human umbilical cord-derived mesenchymal stromal cells (MSC) and MSC-derived hepatocyte-like cells (HLC)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 10

2 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02283879 ↗Injury indicationPHASE1unknown

Human umbilical cord mesenchymal stem cell therapy for patients with cerebral haemorrhage

Cerebral Hemorrhage

Enrolment: 20 · Results not recorded

NCT06122532 ↗Injury indicationNAnot yet recruiting

Umbilical cord mesenchymal stem cells for wound repair in large area burn patients

Large Area Burns

Enrolment: 20 · Results not recorded

NCT02418325 ↗PHASE1/PHASE2terminated

Phase I/II study of allogeneic human umbilical cord tissue-derived MSC and liberation therapy in relapsing remitting multiple sclerosis

Multiple Sclerosis, Relapsing-Remitting

Enrolment: 69 · Results not recorded

NCT03943940 ↗PHASE1/PHASE2unknown

Safety and efficacy of BM-MNC and umbilical cord tissue-derived MSC infusion for type 2 diabetes mellitus

Type 2 Diabetes Mellitus

Enrolment: 60 · Results not recorded

NCT01218464 ↗PHASE1/PHASE2unknown

Phase I/II study of human umbilical cord derived MSC for treatment of liver failure

Liver Failure · Mesenchymal Stem Cells

Enrolment: 70 · Results not recorded

NCT04314011 ↗PHASE1/PHASE2completed

Randomised, double-blind, placebo-controlled study of umbilical cord MSC infusion for aging frailty

Aging Frailty

Enrolment: 30 · Results not recorded

NCT05305833 ↗PHASE1/PHASE2unknown

Stem cell transplantation for temporomandibular joint disease: Phase I/II study

Temporomandibular Joint Disorders · Temporomandibular Joint Osteoarthritis

Enrolment: 20 · Results not recorded

NCT02580695 ↗PHASE1/PHASE2completed

Phase I/II randomised study of umbilical cord-derived MSC in patients with knee osteoarthritis

Osteoarthritis

Enrolment: 30 · Results not recorded

NCT06813027 ↗PHASE1active not recruiting

Allogeneic extracellular secretomes derived from umbilical cord mesenchymal stromal cells: Phase I open-label safety trial

Vitiligo

Enrolment: 13 · Results not recorded

NCT04255147 ↗PHASE1active not recruiting

Mesenchymal stromal cells in extreme preterm infants at risk of developing bronchopulmonary dysplasia (HULC) Phase 1

Bronchopulmonary Dysplasia

Enrolment: 9 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24239106 ↗2013Reported benefit

How important is differentiation in the therapeutic effect of mesenchymal stromal cells in liver disease?

MouseOtherBALB/cMale

Model: Fulminant hepatic failure mouse model

Undifferentiated MSC showed superior rescuing potential to hepatocyte-like cells in fulminant hepatic failure; after hepatic differentiation, HLC expressed lower hepatocyte growth factor and had impaired immunosuppressive capacity.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…